CytomX股票討論區

CX-904 showcased a favorable safety profile, a critical factor in the administration and monitoring of patients in outpatient settings.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...

Pioneering a New Era in Cancer Treatment: CytomX and Merck's Strategic Collaboration on CX-801.
Striding towards revolutionizing cancer therapy, CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced a clinical trial collaboration and supply agreement with pharmaceutical giant Merck (known as MSD outside of the US and Canada). This collaboration is set to explore the therapeutic potential of CX-801, a novel, dually-m...